CFF provided the following clinical trial updates on 10/21/2016:
Description: This open-label study looked at the safety of Aztreonam Inhalation Solution (Cayston®) given three times daily for three 28-day on/28-day off cycles in children with cystic fibrosis and chronic Pseudomonas aeruginosa (PA) infection in the lower airways.
Age: Less than 12 Years
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 8
Length of Participation: 6 months
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT01404234
Use of Utrase MT 12 Enzymes in Young Children with CF Related Pancreatic Insufficiency
Description: This study evaluated the safety and effectiveness of pancrelipase (Ultrase MT 12) in young children with CF.
Age: 2 Years to 6 Years
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 4
Length of Participation: 30 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT00880100
Efficacy and Safety of Ultrase MT20 in Children with CF and Pancreatic Insufficiency
Description: This study looked at the effectiveness and safety of pancrelipase (ULTRASE MT20) in children who have CF and pancreatic insufficiency.
Age: 7 Years to 11 Years
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 6
Length of Participation: 33 days
ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT00513682